{
  "directed": true,
  "graph": {
    "annotation_list": {
      "Custom_Disease": [
        "COVID-19"
      ],
      "PublicationStatus": [
        "Published"
      ],
      "PublicationType": [
        "Letter"
      ],
      "Section": [
        "Full Text"
      ],
      "Type_Of_Infection": [
        "secondary infection"
      ]
    },
    "annotation_pattern": {
      "BioAssay": ".*"
    },
    "annotation_url": {},
    "document_metadata": {
      "authors": "Thrishna",
      "contact": "thrishna@causalitybiomodels.com",
      "copyright": "Copyright © 2020 Fraunhofer Institute SCAI, All rights reserved",
      "description": "COVID Knowledge Curation project",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "name": "32220278.bel",
      "version": "2.0.0"
    },
    "namespace_pattern": {},
    "namespace_url": {
      "CHEBI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns",
      "GFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-genefamily-names-20181221.belns",
      "GO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns",
      "HGNC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns",
      "PFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/pfam/pfam-names-20181024.belns",
      "TAX": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
    },
    "path": "32220278.bel",
    "pybel_version": "0.14.6"
  },
  "links": [
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "Mehta and colleagues postulate that hyperinflammation in coronavirus disease 2019 (COVID-19) could be a driver of severity that is amenable to therapeutic targeting since retro spective data have shown that systemic inflammation is associated with adverse outcome",
      "key": "b428e551de08feb7f4b02dc9e8cc3ef0",
      "line": 50,
      "relation": "increases",
      "source": 11,
      "target": 5
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "However, correlation does not equal causation, and it is equally plausible that increased virus burden (secondary to failure of the immune response to control infection) drives inflammation and consequent severity (as shown for other viruse) rather than augmented inflammation being an inappropriate host response that requires correction.",
      "key": "41ea455fea6991bc0e775820a0cc8507",
      "line": 59,
      "relation": "positiveCorrelation",
      "source": 5,
      "target": 2
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "However, correlation does not equal causation, and it is equally plausible that increased virus burden (secondary to failure of the immune response to control infection) drives inflammation and consequent severity (as shown for other viruse) rather than augmented inflammation being an inappropriate host response that requires correction.",
      "key": "e436ee068b125376807c63337d5c56e9",
      "line": 59,
      "relation": "positiveCorrelation",
      "source": 2,
      "target": 5
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "The authors hypothesise that approaches such as corticosteroids or Janus kinase (JAK) inhibitors could be considered if hyperinflammation is present.",
      "key": "ed025eb6768f8f118e188d4b666dfdc3",
      "line": 65,
      "relation": "decreases",
      "source": 0,
      "target": 5
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "Accordingly, findings from multiple studies in humans and animals indicate that corticosteroid immunosuppression (both inhaled and systemic) impairs induction of anti-viral type-I interferon responses to a range of respiratory viruses,3,4 effects that are likely to also occur in the context of COVID-19.",
      "key": "b74fe01d0fab6ed55cab8305af87ccd8",
      "line": 74,
      "relation": "decreases",
      "source": 0,
      "target": 4
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "The authors hypothesise that approaches such as corticosteroids or Janus kinase (JAK) inhibitors could be considered if hyperinflammation is present.",
      "key": "2289992d2e11817d7fca8b7564769e8e",
      "line": 66,
      "relation": "increases",
      "source": 8,
      "subject": {
        "modifier": "Activity"
      },
      "target": 5
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "Accordingly, findings from multiple studies in humans and animals indicate that corticosteroid immunosuppression (both inhaled and systemic) impairs induction of anti-viral type-I interferon responses to a range of respiratory viruses,3,4 effects that are likely to also occur in the context of COVID-19.",
      "key": "757872bd88902b9315ac55848d219606",
      "line": 75,
      "relation": "increases",
      "source": 4,
      "target": 7
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "JAK-STAT signalling is a major component of the type-I interferon pathway.",
      "key": "898295acab10564ee55c7bc0fbc3ddde",
      "line": 80,
      "relation": "association",
      "source": 7,
      "target": 3
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "JAK-STAT signalling is a major component of the type-I interferon pathway.",
      "key": "465657bedfa8f6535cba7159e9b42472",
      "line": 80,
      "relation": "association",
      "source": 3,
      "target": 7
    },
    {
      "annotations": {
        "BioAssay": {
          "in vitro": true
        },
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "Tofacitinib has been shown to inhibit interferonα production in vitro. Suppression of interferon or other mediators (eg, interleukin 6) could also promote secondary bacterial infection and further complicate the disease course.",
      "key": "1db2ba86e9c9f58d5818c21d965b882e",
      "line": 88,
      "relation": "decreases",
      "source": 1,
      "target": 6
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        },
        "Type_Of_Infection": {
          "secondary infection": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "Tofacitinib has been shown to inhibit interferonα production in vitro. Suppression of interferon or other mediators (eg, interleukin 6) could also promote secondary bacterial infection and further complicate the disease course.",
      "key": "a1425021e7114fab6a18324b0fce958f",
      "line": 91,
      "relation": "decreases",
      "source": 10,
      "subject": {
        "modifier": "Activity"
      },
      "target": 12
    },
    {
      "annotations": {
        "PublicationStatus": {
          "Published": true
        },
        "PublicationType": {
          "Letter": true
        },
        "Section": {
          "Full Text": true
        },
        "Type_Of_Infection": {
          "secondary infection": true
        }
      },
      "citation": {
        "authors": [
          "Ritchie AI",
          "Singanayagam A"
        ],
        "date": "2020-04-04",
        "db": "PubMed",
        "db_id": "32220278",
        "db_name": "Lancet (London, England)",
        "first": "Ritchie AI",
        "last": "Singanayagam A",
        "pages": "1111",
        "volume": "395"
      },
      "evidence": "Tofacitinib has been shown to inhibit interferonα production in vitro. Suppression of interferon or other mediators (eg, interleukin 6) could also promote secondary bacterial infection and further complicate the disease course.",
      "key": "e7d5cd7e33d243649d09c553cb67f4e0",
      "line": 92,
      "relation": "decreases",
      "source": 9,
      "subject": {
        "modifier": "Activity"
      },
      "target": 12
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:corticosteroid)",
      "concept": {
        "name": "corticosteroid",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "a468686acdbd9b5763eec60c73e99320"
    },
    {
      "bel": "a(CHEBI:tofacitinib)",
      "concept": {
        "name": "tofacitinib",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "158eb680ab498b2f29053180998ed8b6"
    },
    {
      "bel": "a(TAX:\"Severe acute respiratory syndrome coronavirus 2\")",
      "concept": {
        "name": "Severe acute respiratory syndrome coronavirus 2",
        "namespace": "TAX"
      },
      "function": "Abundance",
      "id": "c41851da59cc36c21b2e8acf24c1f46d"
    },
    {
      "bel": "bp(GO:\"JAK-STAT cascade\")",
      "concept": {
        "name": "JAK-STAT cascade",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "67c0e73180af1fa505581ac68e0b88ce"
    },
    {
      "bel": "bp(GO:\"immune response\")",
      "concept": {
        "name": "immune response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "a7608eff244d93cdc19d37fbc1489683"
    },
    {
      "bel": "bp(GO:\"inflammatory response\")",
      "concept": {
        "name": "inflammatory response",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "abd32f6c5cca606061975532840db260"
    },
    {
      "bel": "bp(GO:\"interferon-alpha secretion\")",
      "concept": {
        "name": "interferon-alpha secretion",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "a725667301416c2485580c1abbddfa70"
    },
    {
      "bel": "bp(GO:\"type I interferon signaling pathway\")",
      "concept": {
        "name": "type I interferon signaling pathway",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "406286e395b45174d29b736d24d28382"
    },
    {
      "bel": "p(GFAM:\"Jak family tyrosine kinases\")",
      "concept": {
        "name": "Jak family tyrosine kinases",
        "namespace": "GFAM"
      },
      "function": "Protein",
      "id": "25f4313c10d43d7e3c26f7ebadd714e9"
    },
    {
      "bel": "p(HGNC:IL6)",
      "concept": {
        "name": "IL6",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8a1d3c4828c5416eba867c395cc65caa"
    },
    {
      "bel": "p(PFAM:Interferon)",
      "concept": {
        "name": "Interferon",
        "namespace": "PFAM"
      },
      "function": "Protein",
      "id": "fc3e5a25fc63b904f88669c0edd503a7"
    },
    {
      "bel": "path(DO:\"COVID-19\")",
      "concept": {
        "name": "COVID-19",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "6f9f1c2e8012537e503a758c6bfaff0f"
    },
    {
      "bel": "path(DO:\"bacterial infectious disease\")",
      "concept": {
        "name": "bacterial infectious disease",
        "namespace": "DO"
      },
      "function": "Pathology",
      "id": "7311a1ee64446ee88934d6c1ede79e17"
    }
  ]
}